Guides to Israel's cannabis market

Can tourists use cannabis in Israel? Foreign prescriptions have no legal standing, no tourist licence exists, and possession is decriminalised, not legal.

Israeli regulators want medical cannabis patients off smoking and onto oils and metered-dose inhalers. What each format actually is, how they differ in onset and dosing, and what the Israeli evidence shows.

How to get a medical cannabis licence in Israel in 2026 — who can prescribe, how the Health Ministry and HMO routes differ, what it costs, how long approval takes, and what the frozen May 2026 reform would change if it ever revives.

Anxiety and depression are not approved indications in Israel, and the Health Ministry lists severe anxiety as a reason to refuse a permit. Here is why.

How cancer patients in Israel get a medical cannabis licence: who qualifies, which specialist prescribes, what Israeli evidence shows and what it costs.

Israel licenses cannabis for children with autism, epilepsy, Tourette syndrome and cancer. National data shows most families stop within six months.

Chronic pain is the single largest indication for medical cannabis in Israel. How access works, what pain specialists think, and what the outcome data shows.

Israelis over 60 are a large share of medical cannabis patients. Here is what Israel's geriatric studies found about pain, function, side effects and stopping.

How medical cannabis is used for PTSD in Israel — how many patients, full Ministry of Defense funding for combat-related cases, and why the May 2026 plan to narrow who qualifies was frozen three days after it was published.

A breakdown of what medical cannabis really costs in Israel — consultation, licence and pharmacy product — why prices vary, and who is funded.

Which medical conditions can qualify for a cannabis licence in Israel — the approved indications across oncology, pain, neurology, gastroenterology and mental health, and how the 2024 reform changed the rules.

How medical cannabis renewal works in Israel: licence vs HMO prescription, renewal intervals, why 10,000+ patients dropped off after the 2024 reform, and how to avoid a gap.

Israel treats any trace of cannabis in a driver as an offence, and a medical licence is no defence. What the law says, how police test, what it costs.

Decriminalised does not mean legal. The 2019 reform, the 2022 regulations that replaced it, the fines that apply now, and what is still criminal.

What IMC-GAP, IMC-GMP, IMC-GDP and IMC-GSP require — Israel's rulebook for growing, making, distributing and securing medical cannabis.

Is weed legal in Israel in 2026? Medical cannabis is legal by prescription, recreational is not, small-amount possession is decriminalised, CBD is exempt.

CBD is not a dangerous drug in Israel below 0.3% THC. What that exemption actually covers, why food and cosmetics were left out, and what it means for visitors.

A Health Ministry committee proposed phasing out smoked cannabis — then the minister froze it. What the 2026 plan says, and where patients stand.

Where recreational cannabis legalization stands in Israel in 2026 — the current status, the failed bills, the coalition politics blocking reform, and what is actually moving in the Knesset.

What Israel actually does about cannabis possession in 2026 — the fixed fines set by the 2022 regulations, where personal use ends, and when it turns criminal.

A chronological timeline of Israel's medical cannabis programme — from the first approvals in 1992 through per-product pricing, the 2024 HMO reform, and the 2025 expansion of specialist authority.

A profile of IM Cannabis — the Nasdaq-listed operator's 2025 results, its sale of the European business, and its refocus on Israel and a possible US entry.

A profile of InterCure and its Canndoc subsidiary — Israel's largest licensed cannabis producer — covering its model, 2025 financials, stock listings and strategy.

A factual overview of the publicly listed Israeli cannabis companies, how to access them, and the sector-specific risks — not investment advice.

Why Israel — despite world-class research and pharmaceutical standards — is a net cannabis importer rather than an export powerhouse, and which companies actually export.

The story of Bedrocan and the Dutch Office of Medicinal Cannabis — the pioneers who turned cannabis into a standardised pharmaceutical raw material, and set the GMP template Israel's medical-cannabis industry was built to follow.

The universities, centres and clinical programmes that make Israel a world leader in cannabis research — from the Hebrew University's MCCR to the Technion's labs.

How Israeli chemist Raphael Mechoulam isolated THC, discovered the body's own cannabinoids, and made Israel the founding home of modern cannabis science.

A plain-English guide to the endocannabinoid system — the body's own cannabinoid network, much of it discovered through Israeli research — and why it matters for medical cannabis.

What the 'entourage effect' means — the idea, coined by Israeli researchers, that cannabis compounds work better together than in isolation — and what the evidence actually says.

The size and value of Israel's medical cannabis market — revenue figures, the legal-versus-illicit gap, and what the numbers mean for the sector's growth potential.

Israel's medical cannabis patient numbers — a decade of growth, the first-ever decline after the HMO reform, the recovery to a record high, and what's driving the trend.

Where Israel's medical cannabis actually comes from — domestic cultivation versus imports, Canada's dominant role, and why supply is so exposed to trade policy.

How Israel's cannabis market compares to Germany, Canada and the US — small in volume, outsized in research influence, and a net importer in a competitive global trade.